Evidence map›Paper›PMID 36755323›Full record

ArticleJournal of neuroinflammation2023

Genetic models of cleavage-reduced and soluble TREM2 reveal distinct effects on myelination and microglia function in the cuprizone model.

Nicolau Beckmann, Anna Neuhaus, Stefan Zurbruegg, Pia Volkmer, Claudia Patino, Stefanie Joller, Dominik Feuerbach, Arno Doelemeyer, Tatjana Schweizer, Stefan Rudin and 5 more

Open access · goldAbstract read
In one paragraph

Article in Journal of neuroinflammation, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. The role of DAP12 in immune-related inflammatory diseases.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2026
    Review
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Review
  9. Berberine-loaded iron oxide nanoparticles alleviate cuprizone-induced astrocytic reactivity in a rat model of multiple sclerosis.Biometals : an international journal on the role of metal ions in biology, biochemistry, and medicine · 2025
    Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Neutral or Detrimental Effects of TREM2 Agonist Antibodies in Preclinical Models of Alzheimer's Disease and Multiple Sclerosis.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2024
    Article
  15. Article
  16. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 1 institution in 1 country.

Nicolau BeckmannMusculoskeletal Diseases Area, Novartis Institutes for BioMedical Research, Novartis Pharma AG, CH-4002, Basel, Switzerland.
Anna NeuhausNeuroscience, Novartis Institutes for BioMedical Research, Novartis Pharma AG, CH-4002, Basel, Switzerland.
Stefan ZurbrueggNeuroscience, Novartis Institutes for BioMedical Research, Novartis Pharma AG, CH-4002, Basel, Switzerland.
Pia VolkmerNeuroscience, Novartis Institutes for BioMedical Research, Novartis Pharma AG, CH-4002, Basel, Switzerland.
Claudia PatinoNeuroscience, Novartis Institutes for BioMedical Research, Novartis Pharma AG, CH-4002, Basel, Switzerland.
Stefanie JollerNeuroscience, Novartis Institutes for BioMedical Research, Novartis Pharma AG, CH-4002, Basel, Switzerland.
Dominik FeuerbachNeuroscience, Novartis Institutes for BioMedical Research, Novartis Pharma AG, CH-4002, Basel, Switzerland.
Arno DoelemeyerMusculoskeletal Diseases Area, Novartis Institutes for BioMedical Research, Novartis Pharma AG, CH-4002, Basel, Switzerland.
Tatjana SchweizerNeuroscience, Novartis Institutes for BioMedical Research, Novartis Pharma AG, CH-4002, Basel, Switzerland.
Stefan RudinNeuroscience, Novartis Institutes for BioMedical Research, Novartis Pharma AG, CH-4002, Basel, Switzerland.
Ulf NeumannNeuroscience, Novartis Institutes for BioMedical Research, Novartis Pharma AG, CH-4002, Basel, Switzerland.
Ramon BerthNeuroscience, Novartis Institutes for BioMedical Research, Novartis Pharma AG, CH-4002, Basel, Switzerland.
Wilfried FrieauffPreclinical Safety, Novartis Institutes for BioMedical Research, Novartis Pharma AG, CH-4002, Basel, Switzerland.
Fabrizio GaspariniNeuroscience, Novartis Institutes for BioMedical Research, Novartis Pharma AG, CH-4002, Basel, Switzerland.
Derya R ShimshekNeuroscience, Novartis Institutes for BioMedical Research, Novartis Pharma AG, CH-4002, Basel, Switzerland. derya.shimshek@novartis.com.
Novartis (Switzerland) · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Triggering receptor expressed on myeloid cells 2 (TREM2) is a cell-surface immunoreceptor expressed on microglia, osteoclasts, dendritic cells and macrophages. Heterozygous loss-of-function mutations in TREM2, including mutations enhancing shedding form the cell surface, have been associated with myelin/neuronal loss and neuroinflammation in neurodegenerative diseases, such as Alzheimer`s disease and Frontotemporal Dementia. Using the cuprizone model, we investigated the involvement of soluble and cleavage-reduced TREM2 on central myelination processes in cleavage-reduced (TREM2-IPD), soluble-only (TREM2-sol), knockout (TREM2-KO) and wild-type (WT) mice. The TREM2-sol mouse is a new model with selective elimination of plasma membrane TREM2 and a reduced expression of soluble TREM2. In the acute cuprizone model demyelination and remyelination events were reflected by a T2-weighted signal intensity change in magnetic resonance imaging (MRI), most prominently in the external capsule (EC). In contrast to WT and TREM2-IPD, TREM2-sol and TREM2-KO showed an additional increase in MRI signal during the recovery phase. Histological analyses of TREM2-IPD animals revealed no recovery of neuroinflammation as well as of the lysosomal marker LAMP-1 and displayed enhanced cytokine/chemokine levels in the brain. TREM2-sol and, to a much lesser extent, TREM2-KO, however, despite presenting reduced levels of some cytokines/chemokines, showed persistent microgliosis and astrocytosis during recovery, with both homeostatic (TMEM119) as well as activated (LAMP-1) microglia markers increased. This was accompanied, specifically in the EC, by no myelin recovery, with appearance of myelin debris and axonal pathology, while oligodendrocytes recovered. In the chronic model consisting of 12-week cuprizone administration followed by 3-week recovery TREM2-IPD displayed sustained microgliosis and enhanced remyelination in the recovery phase. Taken together, our data suggest that sustained microglia activation led to increased remyelination, whereas microglia without plasma membrane TREM2 and only soluble TREM2 had reduced phagocytic activity despite efficient lysosomal function, as observed in bone marrow-derived macrophages, leading to a dysfunctional phenotype with improper myelin debris removal, lack of remyelination and axonal pathology following cuprizone intoxication.

Indexed as

Demyelinating DiseasesMembrane GlycoproteinsReceptors, ImmunologicAnimalsCuprizoneCytokinesDisease Models, AnimalMiceMice, Inbred C57BLMice, KnockoutMicrogliaModels, GeneticMyelin SheathNeuroinflammatory DiseasesCuprizoneCytokinesMembrane GlycoproteinsReceptors, ImmunologicTrem2 protein, mouseCuprizoneMicrogliaMRINeuroinflammationPhagocytosisTREM2

Identifiers

PMID36755323
PMCPMC9909920
OpenAlexW4319593075

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.